Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Sustained-release drug delivery systems are fundamentally changing how Alzheimer’s disease is treated by allowing medications to work more effectively in the brain over extended periods. Instead of relying on daily pills that produce inconsistent blood levels throughout the day, these advanced systems deliver therapeutic compounds steadily and directly to target sites, which significantly improves both efficacy and tolerability for patients. For example, donepezil formulated in solid lipid nanoparticles demonstrates sustained release over 12 hours compared to immediate-release versions, meaning patients experience more stable symptom relief without the peaks and valleys that come with conventional tablets.
The clinical impact of this shift is substantial. Two recently approved monoclonal antibodies—lecanemab and donanemab—represent the first disease-modifying treatments that actually slow cognitive decline in early-stage Alzheimer’s disease, showing 25-35% slowing of disease progression. Both of these breakthrough medications rely on novel delivery methods, including subcutaneous autoinjector formulations that bypass the digestive system entirely. What was once a pipeline of symptomatic-only treatments has transformed into a field where modified delivery systems are the cornerstone of therapeutic advancement, with 182 clinical trials currently assessing 138 different drugs designed to address Alzheimer’s at its biological root.
Table of Contents
- How Do Sustained-Release Drug Delivery Systems Improve Alzheimer’s Drug Effectiveness?
- Nanoparticle Technologies Advancing Alzheimer’s Care
- FDA-Approved Treatments with Enhanced Delivery Formulations
- Clinical Pipeline Progress in Alzheimer’s Drug Development
- Challenges and Limitations of Next-Generation Delivery Systems
- Emerging Technologies and Future Treatments
- What These Advances Mean for Patients and Caregivers
- Conclusion
How Do Sustained-Release Drug Delivery Systems Improve Alzheimer’s Drug Effectiveness?
Sustained-release technology works by encapsulating Alzheimer’s medications within nanoparticles or polymeric matrices that gradually release the active compound over hours or days, maintaining therapeutic levels in the bloodstream without requiring multiple daily doses. The most commonly used backbone for this approach is PLGA (poly lactic-co-glycolic acid), an FDA-approved polymer that offers flexibility in release timing, complete biodegradability, and the ability to create particles at the nanoscale—small enough to potentially cross the blood-brain barrier more effectively than free drug molecules. This represents a fundamental advantage over immediate-release tablets, which cause medication levels to spike after administration and then decline before the next dose, leaving patients in windows of suboptimal treatment.
Rivastigmine, a cholinesterase inhibitor used in Alzheimer’s care, exemplifies this improvement when formulated as polymeric nanoparticles capable of sustained release for 72 hours. In studies, this extended-release formulation not only maintained therapeutic drug levels longer but also demonstrated improved safety profiles with fewer gastrointestinal side effects—a common complaint with conventional formulations taken multiple times daily. The consistency of brain exposure to the medication translates to more stable cognitive benefits and better quality of life for patients who no longer experience the “wearing off” phenomenon between doses.
Nanoparticle Technologies Advancing Alzheimer’s Care
Solid lipid nanoparticles (SLN) represent a distinct approach within the nanoparticle family, using lipid-based cores rather than polymers to encapsulate drugs like donepezil. These formulations achieved 12-hour sustained release in laboratory studies, compared to the much shorter duration of conventional donepezil tablets that typically require dosing twice daily. The lipid-based structure mimics the body’s own transport mechanisms, potentially improving how the drug crosses into the brain and is taken up by affected neurons. However, there’s an important limitation: while these nanoparticle systems show promising pharmacokinetics in controlled studies, translating this promise into widespread clinical use requires demonstrating that patients actually experience meaningful cognitive or functional benefits, not just better drug levels.
One significant challenge in nanoparticle-based delivery is manufacturing consistency and scale-up. Producing nanoparticles with identical size distribution, drug loading, and release profiles is far more complex than manufacturing conventional tablets, and this complexity can affect costs, shelf stability, and regulatory approval timelines. Additionally, while PLGA polymers are biocompatible and approved for clinical use, the body’s immune response to repeated nanoparticle exposure—particularly with frequent dosing—remains an area requiring careful study. For Alzheimer’s patients who are typically elderly with multiple comorbidities, any additional systemic effects must be weighed carefully against therapeutic benefit.
FDA-Approved Treatments with Enhanced Delivery Formulations
The FDA approval landscape for Alzheimer’s treatment shifted dramatically with the clearance of lecanemab (Leqembi), a monoclonal antibody that targets amyloid-beta aggregates in the brain and has demonstrated the ability to slow cognitive decline by 25-35% in early-stage disease. Beyond the biological breakthrough, lecanemab exemplifies how delivery method is inseparable from therapeutic success: the drug is administered as a biweekly intravenous infusion or, more recently approved in 2025, as a subcutaneous autoinjector formulation that patients can self-administer at home. This shift to subcutaneous delivery dramatically improves accessibility and quality of life, eliminating the need for regular clinic visits and infusion center infrastructure.
Donanemab (Kisunla), another monoclonal antibody with similar cognitive benefits (25-35% slowing of decline), similarly relies on intravenous infusion but with a different dosing schedule designed to minimize amyloid-related imaging abnormalities (ARIA)—a safety consideration where sustained, controlled drug exposure becomes critically important. In May 2026, the FDA is expected to make a decision on lecanemab starter doses that would allow at-home subcutaneous administration by patients themselves, further expanding access. These approvals represent not just new drugs, but new delivery paradigms where the administration method is integral to the treatment strategy and directly impacts patient adherence and real-world outcomes.
Clinical Pipeline Progress in Alzheimer’s Drug Development
The current Alzheimer’s drug development pipeline as of early 2025 comprises 182 clinical trials assessing 138 distinct drugs—a remarkable expansion from just a handful of agents a decade ago. These trials are distributed across development phases: 48 Phase 3 trials (the final stage before potential FDA approval) testing 31 drugs, 86 Phase 2 trials testing 75 drugs, and 48 Phase 1 trials testing 45 drugs. This distribution is important because it signals that the field is not just maintaining momentum from lecanemab and donanemab approvals, but actively advancing multiple new mechanisms simultaneously. Of these 138 drugs, 30 percent are biological disease-targeted therapies (like monoclonal antibodies), 43 percent are small-molecule drugs (traditional pill-based compounds), 14 percent focus on cognitive enhancement, and 11 percent target behavioral and neuropsychiatric symptoms that accompany cognitive decline.
This diversity in mechanism and approach reflects a fundamental understanding that Alzheimer’s disease is heterogeneous—different patients have different pathological drivers and different symptom profiles. Some pipeline drugs target amyloid pathology directly, others target tau tangles, and others address neuroinflammation or neurodegeneration. This parallel approach to drug development means that even if an individual drug fails in trials or proves ineffective for a particular patient, the field has multiple alternative candidates in advanced testing stages. The existence of this robust pipeline also drives innovation in delivery technologies, as companies developing these new entities recognize that an effective drug will only achieve its full potential if it can reliably reach the brain and maintain therapeutic levels.
Challenges and Limitations of Next-Generation Delivery Systems
Despite the promise of sustained-release and enhanced delivery technologies, significant challenges remain. First, the blood-brain barrier represents a fundamental biological obstacle that even sophisticated nanoparticles struggle to overcome consistently. Many experimental Alzheimer’s drugs fail not because they’re ineffective at their molecular targets, but because they cannot reliably penetrate the brain tissue in sufficient concentrations. Second, some of the most advanced delivery methods—particularly intravenous and subcutaneous biologics like lecanemab and donanemab—require either regular clinic visits or patient self-injection capability, which creates barriers for elderly patients with mobility issues, transportation limitations, or cognitive impairment that makes complex medication administration difficult.
A third critical limitation is the risk-benefit calculation for early intervention. Lecanemab and donanemab provide 25-35% slowing of cognitive decline, which is clinically meaningful but not curative, and both carry risks of amyloid-related imaging abnormalities (ARIA), including brain microhemorrhages and microinfarcts that may not produce immediate symptoms but could have long-term consequences. Patients must also be screened for amyloid pathology before treatment, usually requiring PET imaging or cerebrospinal fluid testing—procedures that are expensive, not widely available, and require patient cooperation. For patients in mild cognitive impairment stages, the trade-off between disease modification and safety risks requires careful shared decision-making with clinicians.
Emerging Technologies and Future Treatments
Roche’s trontinemab represents one of the most closely watched investigational therapies in the Alzheimer’s pipeline, with Phase 3 trials (TRONTIER 1 and 2) planned for later 2025. Trontinemab targets tau pathology rather than amyloid, addressing a different aspect of the Alzheimer’s disease process that remains relatively underexploited compared to amyloid-targeting drugs. If successful, trontinemab could open a new therapeutic category and potentially be combined with amyloid-targeting agents like lecanemab or donanemab for more comprehensive disease modification.
The development of tau-targeted therapies also drives innovation in delivery methods, as tau pathology is distributed differently throughout the brain than amyloid, potentially requiring different approaches to drug distribution and targeting. Beyond specific drug candidates, emerging technologies include intranasal delivery systems that could potentially bypass the blood-brain barrier more effectively, implantable sustained-release systems that could provide consistent drug delivery for months, and targeted nanoparticles designed to bind specifically to amyloid or tau pathology. These approaches remain largely experimental, but several are entering early human testing. The field is also exploring combination therapies where multiple drugs with different mechanisms are administered together, requiring delivery systems sophisticated enough to balance the pharmacokinetics of multiple compounds simultaneously.
What These Advances Mean for Patients and Caregivers
The advancement from symptomatic treatments (like donepezil and rivastigmine, which temporarily improve cognition but don’t slow disease progression) to disease-modifying therapies represents a fundamental shift in Alzheimer’s care philosophy. For patients diagnosed in early stages with confirmed amyloid pathology, the availability of lecanemab and donanemab—particularly with the expanding option of subcutaneous self-administration—offers genuine hope of slowing cognitive decline rather than simply managing symptoms as the disease progresses. However, this hope comes with complexity: identifying eligible patients requires early diagnosis and biomarker testing that remains inaccessible to many, particularly in rural areas or lower-income communities.
For caregivers, the expanding pipeline of treatments offers the possibility that patients diagnosed in coming years may have access to multiple disease-modifying options, potentially tailored to different Alzheimer’s subtypes or pathological profiles. The movement toward at-home delivery formulations also eases the burden of regular clinic visits. As the field matures and more drugs enter the pipeline—182 trials testing 138 candidates as of 2025—the probability increases that any individual patient will find a treatment regimen that addresses their specific disease mechanism and life circumstances. The next frontier will be ensuring that these advances reach all populations equitably, not just those with access to specialized dementia centers and the resources for advanced diagnostic testing.
Conclusion
Sustained-release and enhanced delivery systems have become central to Alzheimer’s therapeutic innovation, enabling disease-modifying treatments that were impossible with conventional oral formulations. The approvals of lecanemab and donanemab, combined with a robust pipeline of 182 clinical trials testing 138 new drugs, demonstrate that the field has moved beyond symptomatic management into a new era where multiple disease-modifying approaches are becoming available. These advances in drug delivery—from nanoparticle encapsulation to subcutaneous autoinjectors to targeted biologics—directly enable the efficacy and patient acceptance that make these treatments transformative.
For patients and families facing Alzheimer’s disease, these developments offer more treatment options and the possibility of slowing cognitive decline, particularly when diagnosis occurs early enough to identify amyloid or tau pathology. The key challenge now is ensuring that these advances extend beyond specialized centers to all communities, that diagnostic infrastructure expands to identify eligible patients, and that ongoing research continues to optimize both the drugs themselves and the delivery systems that make them effective. As more pipeline candidates enter clinical testing and eventual FDA review, the landscape of Alzheimer’s care will continue to shift toward precision, prevention, and true disease modification rather than management of inevitable decline.
You Might Also Like
- Drug Development Portfolio Analysis Reveals Alzheimer’s Treatment Trends
- Market Analysis Examines Future of Alzheimer’s Treatment Industry
- High-Content Screening Identifies New Compounds for Alzheimer’s Treatment
For more, see Alzheimer’s Association — caregiving.
